SRT6
SRT6, an anticancer agent is a CD44 inhibitor. SRT6 inhibits key CD44-associated kinases, including SRC, ERBB2 and MAPKAPK2. SRT6 has strong tumor selectivity over non-tumoral lung cells and significant antiproliferative activity against cancer cells (EC50of 1.37 μM for NCI-H23 cells) [1].
Product Specifications
UNSPSC
12352005
Target
CD44; EGFR; MAPKAPK2 (MK2) ; Src
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=S(C1=CC=C([N+]([O-])=O)C=C1)(OC2=CC=CC3=C2CCN(CC4=CC(OC)=C(OC)C(OC)=C4)C3)=O
Molecular Formula
C25H26N2O8S
Molecular Weight
514.55
References & Citations
[1]Romero-Tamudo S, et al. CD44-targeted N-benzyltetrahydroisoquinoline derivatives as anticancer agents with high tumor-to-normal cell selectivity. Eur J Med Chem. 2025 Nov 15;298:118039.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
